Johnson & Johnson Statistics By Sales, Region, Segments, Top Pharmaceutical Products, Franchise, Revenue, Net Earning And Demographics

Introduction

Johnson & Johnson Statistics: Johnson & Johnson (J&J) is a global leader in healthcare, offering a wide range of products in pharmaceuticals, medical devices, and consumer health. In 2024, it will continue to maintain its position as a powerhouse in the healthcare sector, driven by innovation, strategic acquisitions, and a strong commitment to sustainability. This article has covered all essential analyses of the platform’s current trends from different insights and will guide you accordingly.

Editor’s Choice

• Johnson & Johnson Statistics show that for the quarter ending June 30, 2024, Johnson & Johnson reported a revenue of USD 22.447 billion, reflecting a 4.31% year-over-year increase.
• In the second quarter ending June 30, 2024, Johnson & Johnson reported a gross profit of USD 15.578 billion, a 3.46% increase from last year.
• During the same period, Johnson & Johnson’s net earnings were USD 6.5 billion, up 2.5% from 2023.
• The Pharmaceuticals segment remains the largest contributor to J&J’s revenue, accounting for approximately 55% of the total revenue in 2024, which amounts to approximately USD 13 billion in the second quarter of the year.
• North America remains the company’s largest market, contributing nearly 50% of its total revenue.
• Johnson & Johnson Statistics further elaborates that in 2024, the company allocated almost USD 12 billion to R&D, which is 11.5% of its total revenue.
• In recent years, the company has made key acquisitions, including the purchase of a biotechnology company specializing in gene therapy.
• As of 2024, J&J uses 85% renewable energy across its global operations, with a target of reaching 100% by 2025.
• By the end of 2023, Johnson & Johnson had about 132,000 employees working for the company.
• In June 2024, the price of Johnson & Johnson’s share was 146.16 U.S. dollars.

Top Five Cool Facts from Johnson & Johnson

• Johnson & Johnson was among the first to mass-produce sterile surgical supplies. In 1886, it introduced ready-to-use dressings and sutures, which greatly reduced surgery-related infections.
• Johnson & Johnson invented the first commercial first-aid kit in 1888, originally for railroad workers.
• In 1920, J&J employee Earle Dickson invented the Band-Aid for his wife. It soon became a huge success, with over 100 billion sold worldwide, making it a healthcare icon.
  ● Johnson & Johnson introduced Johnson’s Baby Powder in 1894 as the first of its kind, and it quickly became a popular baby care product known for soothing skin irritations.
• In the 1960s, Johnson & Johnson’s Ethicon developed a special adhesive for sealing wounds in space, which was used during Apollo missions to ensure astronaut safety.

You May Also Like To Read

• ai chips statistics
• ai in healthcare statistics
• internet of things statistics
• fitness industry statistics
• mental health statistics

General Johnson & Johnson Statistics

• Johnson & Johnson was founded in the year 1886 and has grown to become one of the most recognised names in healthcare worldwide.
• The company is headquartered in New Brunswick, New Jersey, USA.
• In 2024, Johnson & Johnson’s total revenue is projected to be around USD100 billion.
• Johnson & Johnson Statistics further states that this is the highest-ranked pharmaceutical company in the United States based on revenue, and the company is supposed to make over 85 billion U.S. dollars worldwide.
• As of 2024, Johnson & Johnson employs approximately 150,000 people globally.
• Johnson & Johnson operates across three primary business segments, the pharmaceuticals segment of which will account for the highest revenue, USD 52 billion.
• Top products include oncology drugs like Imbruvica and Darzalex, as well as immunology drugs such as Stelara.
• Johnson & Johnson made strategic acquisitions in the biotechnology and gene therapy sectors to expand its product portfolio and enhance its innovation capabilities.
• The company has invested in programs targeting improving healthcare access in underserved regions and advancing medical research.
• Johnson & Johnson Statistics reports that the company aims to achieve 100% renewable energy usage by 2025.

Stock Key Data (TTM) Statistics of Johnson & Johnson, 2024

Johnson & Johnson’s Sales Statistics

(Reference: statista.com)

• A report published by Statista states that in 2023, Johnson & Johnson made around 95 billion U.S. dollars in sales, a decrease from 2022, accounting for 94.94 billion U.S. dollars.
• However, it is estimated to reach approximately USD 100 billion by the end of 2024.

By Region

(Reference: statista.com)

• Johnson & Johnson Statistics in 2023 reports that Johnson & Johnson made over 46,444 million U.S. dollars in sales in the United States.
• Furthermore, other regions with total Johnson & Johnson sales in the same period were Europe (USD 20,410 million), Asia-Pacific, Africa (USD 13,756 million), and the Western Hemisphere (USD 4,549 million).

Moreover, in 2024, Johnson & Johnson continued to demonstrate its global reach, and the table below includes overall significant sales contributions from various regions around the world.

By Segments

(Reference: statista.com)

• Johnson & Johnson Statistics in 2023 also show that the pharmaceutical segment brought in almost 54,759 million U.S. dollars in sales worldwide, making it the company’s top performer.
• Moreover, the total sales accounted for medical devices and diagnostics was around USD 30,400 million.

The table below states the sales of Johnson & Johnson worldwide by segment in 2024:

Sales of Johnson & Johnson Statistics By Top Pharmaceutical Products

Sales of Johnson & Johnson’s Consumer Healthcare Segment By Franchise

Sales of Johnson & Johnson’s Medtech Segment Statistics By Franchise

(Reference: statista.com)

• As mentioned in Johnson & Johnson Statistics 2023, the medtech segment, which includes medical devices and diagnostics, earned around 10,037 million U.S. dollars, specifically from its surgery franchise.
• Besides, sales of Johnson & Johnson’s medical technology segment in 2023 by franchise were Orthopaedics (USD 8,942 million), Vision care (USD 5,072 million), and Interventional Solutions (USD 6,350 million).

The table below delivers the 2024 sales of Johnson & Johnson’s Medtech Segment analyses by franchise.

Revenue of Johnson & Johnson’s Consumer Health Segment Statistics

(Reference: statista.com)

In the year 2024, the expected global revenue generated by Johnson & Johnson’s consumer healthcare segment is skin care (USD 4.54 billion), OTC drugs and nutritionals (USD 4.04 billion), baby care (USD 1.86 billion), and others (USD 2.96 billion).

Johnson & Johnson Net Earning Statistics

(Reference: statista.com)

• In 2023, Johnson & Johnson’s net earnings were around 35,153 million U.S. dollars, which is a big increase from the previous year when they were about 17,941 million U.S. dollars.
• Johnson & Johnson Statistics in 2024 further show that the company’s net earnings are expected to be around USD 36.5 billion.

J&J’s Expenditure Statistics On Research And Development

(Reference: statista.com)

• Johnson & Johnson spent over 15,085 million U.S. dollars on research and development in 2023, which increased from USD 14,135 million in 2022.
• In addition, the company allocated approximately USD 16 billion to R&D in 2024.
• Meanwhile, R&D spending accounted for about 16% of the company’s total revenue.

Johnson & Johnson Statistics By Revenue

(Reference: statista.com)

The Statista report further analyses state that Johnson & Johnson’s total revenue is expected to be around USD 80.49 billion, an increase from last year’s USD 80.18 billion.

(Source: macrotrends.net)

• The total revenue for the first quarter of 2024 was around USD 21.383 billion, up 2.34% from the previous quarter, followed by the second quarter, resulting in USD 22.447 billion (+4.31%).
• Meanwhile, other quarterly revenue-earning and YoY quarterly growth in 2023 are followed by Q1: USD 20.894 billion (-10.81%), Q2: USD 21.519 billion (-10.41%), Q3: USD 21.351 billion (+6.78%), and Q4: USD 21.395 billion (+70.51%).

By Gross Profit

(Source: macrotrends.net)

• As of June 30, 2024, Johnson & Johnson’s gross profit was 15.578 billion, a 3.46% increase compared to the same period last year.
• Meanwhile, the company’s gross profit was USD 14.872 billion (+4.68%) in the first quarter of this year.
• Johnson & Johnson Statistics further states that the quarterly gross profits and annual growth rate of 2023 were USD 14.207 billion (-10.24%), USD 15.057 billion (-6.48%), USD 14.745 billion (+6.66%), and USD 14.597 billion (+51.41%).

By Operating Income (O.I.), 2024

(Source: macrotrends.net)

By EBITDA

(Source: macrotrends.net)

By Net Income

(Source: macrotrends.net)

By Earning Per Share (EPS)

(Source: macrotrends.net)

By Shares Outstanding

(Source: macrotrends.net)

• As mentioned in Johnson & Johnson Statistics, by the end of the first and second quarters of 2024, the share outstanding accounted for around 2.430 billion (-6.75%) and 2.422 billion (-7.77%), respectively.
• Meanwhile, another quarterly share outstanding and YoY growth rates in 2023 were Q1: 2.606 billion (-2.29%), Q2: 2.626 billion (-1.57%), Q3: 2.550 billion (-4.17%), and Q4: 2.560 billion (-3.90%).

Johnson & Johnson Statistics By Stock Price Performance

(Source: forbes.net)

A report published by Forbes states the monthly stock price performance of Johnson & Johnson in 2024 is detailed below:

Johnson & Johnson’s Comparison Statistics By Q1 Regional Sales

By Q1 Segmental Sales

Johnson & Johnson Website Traffic Statistics By Country

(Reference: similarweb.com)

• As of July 2024, the total number of website visits to jnj.com to date reached 2.5 million, increasing by 6.83% from last month and securing a 38.4% bounce rate.
• Johnson & Johnson Statistics 2024: the United States had 44.84% of the website’s total traffic, which has increased by 10.03%.
• During the same duration, other countries recorded the following contributions in total traffic: Netherlands: 4.72% (-3.64%), Switzerland: 4.38% (-0.8%), China: 4.25% (+10.14%), and Uruguay: 4.2% (+61.8%).
• Other countries collectively made up around 37.61% of visitors shared on jnj.com.

By Demographics

(Reference: similarweb.com)

• In July 2024, male and female users of jnj.com were 43,94% and 56.06%, respectively.
• The Johnson and Johnson Statistics by age group states that the highest number of website users observed is between 25 and 34 years old, which is 37.23%.
• 19.97% of Johnson & Johnson website users are aged 35 to 44 years.
• In contrast, 16.33% and 12.11% belong to individuals aged 45 to 54 and 18 to 24, respectively.
• Around 9.13% of J&J website users are aged from 55 to 64 years.
• People above 65 years of age contributed 5.23 % of user shares of jnj.com.

By Traffic Source

(Reference: similarweb.com)

• Johnson & Johnson Statistics 2024 also shows that direct search generated the highest traffic rate to jnj.com, 44.82%.
• Almost 34.42% of the share comprises organic search traffic searches, while 16.54% is from referrals.
• Others are followed by paid searches (2.14%), social media (1.77%), mail (0.14%), and display (0.18%).

By Social Media Referral Statistics

(Reference: similarweb.com)

• LinkedIn had the highest social media referral rate, with a 64.77% share compared to other social network traffic on the Johnson and Johnson website.
• YouTube and Whatsapp each contributed a share of 20.22% and 10.2% on jnj.com.
• Around 1.15% and 0.9% of website traffic were accounted for by Reddit and Facebook in July 2024.
• As per Johnson & Johnson Statistics, other social media segments collectively accounted for 2.75%.

Top 10 Biotech And Pharmaceutical Companies Statistics By Market Cap

(Reference: similarweb.com)

• Eli Lilly and Co., U.S., captured the top market capitalization among the top 10 global biotech and pharmaceutical companies worldwide as of March 2024, resulting in USD 738.8 billion.
• Novo Nordisk (USD 427.8 billion) and Johnson & Johnson (USD 385.3 billion) generated the second and third-highest market caps in the same period, respectively.
• Other Leading biotech and pharmaceutical companies market caps in 2024 are followed by AbbVie Inc. (USD 316.5 billion), Merck & Co Inc. (USD 311.1 billion), Novartis AG (USD 233.1 billion), Roche Holding AG (USD 216.9 billion), AstraZeneca PLC (USD 199 billion), Amgen Inc. (USD 148.3 billion), and Pfizer Inc. (USD 147.3 billion).

Recent Product Launches Of Johnson & Johnson In 2024

Demand-Influencing Factors For Johnson & Johnson

Economic Conditions:

• As mentioned in Johnson & Johnson Statistics, the global economy grew by 3.2% in 2024, impacting Johnson & Johnson’s product demand differently across its segments.
• Economic growth is emerging in overall markets like India and China, where the GDP grew by 6.1% and 5.4%, respectively.
• Inflation in the U.S., at 4.6% this year, has made consumers more careful with their spending, especially on health products.

Ageing Population:

• In 2024, around 11% of the global population, or about 885 million people, were aged 65 and above, driving demand for Johnson & Johnson’s products.
• The demand for J&J’s oncology drugs grew by 7%, boosting the company’s revenue in this area.

Technological Advancements:

• Johnson & Johnson Statistic further states that the rapid growth of digital health technologies, like telemedicine and wearable devices, increased by 15% in 2024, making the market worth USD 185 billion.
• J&J’s focus on digital health, such as A.I. tools and wearable devices, led to a 5% rise in their medical devices revenue.

Regulatory Environment

• In 2024, quick FDA approvals, including for a new autoimmune drug, helped boost demand for Johnson & Johnson’s products.
• Stricter regulations in the European Union have made it harder for Johnson & Johnson to enter the market, which might reduce demand in those areas.

Consumer Preferences

• In recent years, the global market for sustainable products grew by 10% to USD 150 billion, boosting demand for Johnson & Johnson’s natural and eco-friendly products.
• The company has launched eco-friendly Neutrogena products with biodegradable packaging, leading to a 4% sales increase.

Healthcare Access And Infrastructure

• Johnson & Johnson Statistics also show that in 2024, global healthcare spending is expected to rise by 4% to USD 8.8 trillion, which will significantly impact the demand for Johnson & Johnson’s products.
• J&J’s sales in the Asia-Pacific region increased by 8%, mainly because of higher healthcare spending in India and Indonesia.
• The global telehealth market grew by 14%, leading to increased demand for J&J’s wearable health devices.

Johnson & Johnson Statistics By Sustainable Initiatives

• In 2024, the company reduced its greenhouse gas emissions by 8%, which is a substantial step towards its long-term goal.
• This reduction was achieved by installing solar panels at manufacturing sites, which now provide 20% of the company’s energy needs.
• Neutrogena’s 2024 product line uses 100% recyclable packaging, helping reduce plastic waste by 10% in J&J’s consumer health products.
• As per Johnson & Johnson Statistics, the company has reduced its water usage by 12%, saving about 1.5 billion liters, as part of its goal to cut water use by 20% by 2025.
• J&J launched eco-friendly Aveeno skincare products with sustainably sourced ingredients, and due to strong demand, they earned USD 500 million in sales in the first six months.
• By 2024, around 50% of J&J’s manufacturing sites had achieved zero-waste status, diverting over 99% of waste from landfills and reducing overall waste by 15% compared to last year.
• By the year’s end, Johnson & Johnson had invested $300 million in wind and solar energy.
• At the same time, almost 60% of the company’s electricity comes from renewable sources, and it aims for 100% by 2025.

Conclusion

Johnson & Johnson Statistics has explained a robust performance across its key business segments, driven by strategic product launches, technological innovation, and a strong focus on sustainability. The company’s financial performance also played an effective role, marked by a 6% increase in overall revenue, demonstrating its strong ability to navigate a complex global market while effectively meeting the changing needs of healthcare providers and consumers.

As J&J moves forward, the company’s potential to innovate and adapt to changing market algorithms will be important in maintaining its competitive edge and driving continued growth in the years to come.

Maitrayee Dey

Maitrayee, after completing her graduation in Electrical Engineering, transitioned into the world of writing following a series of technical roles. She specializes in technology and Artificial Intelligence, bringing her experience as an Academic Research Analyst and Freelance Writer, with a focus on education and healthcare under the Australian system. From an early age, writing and painting have been her passions, leading her to pursue a full-time career in writing. In addition to her professional endeavors, Maitrayee also manages a YouTube channel dedicated to cooking.

More Posts By Maitrayee Dey

Studio Ghibli Statistics By Site Rating, Number Of Publications And Japanese Box Office

TripAdvisor Statistics By Country, Revenue, Users, Operating Income And Demographics

Dropshipping Statistics By Market Size, Media Usage, Beauty Products, Sales, Demographic, Revenue And Profit

Trucking Industry Statistics By Operating Cost And Regions

Income Tax Statistics By Revenues And Forecast, Tax Retures Filed And Tax Paid And Trend

TVFPlay Statistics By Revenue, Subscribers And VideoViewers

Checkout.com Statistics By Country, Website Traffic, Companies Usage And Demographics

Workplace Collaboration Statistics By Job Level, Employee Effects And Employee Get to Gather

MobiKwik Statistics By Revenue, Financials, Marketing, Website Traffic And Usage

CRISPR Statistics By Startups And Facts